Helus Pharma Partners with TARA Mind to Boost Veteran Mental Health Outreach
Collaboration overview
Helus Pharma (NASDAQ: HELP) announced a partnership with mental‑health platform TARA Mind to support veteran mental health and accelerate recruitment into Helus’ Phase 3 PARADIGM trial of HLP003 for major depressive disorder. The collaboration also involves Veterans Exploring Treatment Solutions (VETS), which will help engage veterans and connect them with clinical research opportunities.
Focus on HLP003 Phase 3 in veterans
HLP003, a novel serotonergic agonist being developed as an adjunctive treatment for major depressive disorder, has received Breakthrough Therapy designation from the U.S. FDA. TARA Mind and VETS will use their networks to help identify and recruit veterans for the ongoing HLP003 Phase 3 PARADIGM program, aiming to improve awareness of innovative, research‑based options among communities with high rates of depression, PTSD, and suicide risk.
Alignment with new U.S. policy
The initiative is framed as aligning with President Donald Trump’s April 18, 2026 Executive Order encouraging development and evaluation of innovative medical treatments for serious mental illness, including in veteran populations. Helus Pharma’s leadership has positioned the partnership as part of a broader shift toward an integrated neuro‑therapeutics platform focused on novel treatment regimens and expanded access to clinical research.
